Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$17.89
0.643.71%
At close: -
$17.69
-0.20-1.12%
After Hours: 7:58 PM EDT
Comments
Loading...
Beam Therapeutics Analyst Ratings and Price Targets | NASDAQ:BEAM | Benzinga
Beam Therapeutics Inc has a consensus price target of $51.85 based on the ratings of 21 analysts. The high is $113 issued by SVB Leerink on August 10, 2022. The low is $25 issued by Barclays on May 7, 2025. The 3 most-recent analyst ratings were released by Guggenheim, Wells Fargo, and Barclays on May 7, 2025, respectively. With an average price target of $50 between Guggenheim, Wells Fargo, and Barclays, there's an implied 182.65% upside for Beam Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
Wells Fargo
Barclays
HC Wainwright & Co.
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Beam Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/07/2025 | Buy Now | 210.92% | Guggenheim | Debjit Chattopadhyay49% | $78 → $55 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | 295.71% | Wells Fargo | Yanan Zhu39% | $75 → $70 | Maintains | Overweight | Get Alert |
| 05/07/2025 | Buy Now | 41.33% | Barclays | Gena Wang49% | $31 → $25 | Maintains | Equal-Weight | Get Alert |
| 04/07/2025 | Buy Now | 352.25% | HC Wainwright & Co. | Patrick Trucchio45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2025 | Buy Now | 137.43% | B of A Securities | Alec Stranahan33% | $42 → $42 | Upgrade | Neutral → Buy | Get Alert |
| 03/12/2025 | Buy Now | — | Cantor Fitzgerald | Rick Bienkowski27% | — | Reiterates | Overweight → Overweight | Get Alert |
| 03/10/2025 | Buy Now | 126.12% | Scotiabank | Greg Harrison48% | → $40 | Upgrade | Sector Perform → Sector Outperform | Get Alert |
| 03/10/2025 | Buy Now | 92.2% | Jones Trading | Soumit Roy33% | → $34 | Upgrade | Hold → Buy | Get Alert |
| 03/10/2025 | Buy Now | 352.25% | HC Wainwright & Co. | Patrick Trucchio45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2025 | Buy Now | 41.33% | Scotiabank | Greg Harrison48% | $24 → $25 | Maintains | Sector Perform | Get Alert |
| 02/28/2025 | Buy Now | 352.25% | HC Wainwright & Co. | Patrick Trucchio45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 340.94% | Guggenheim | Debjit Chattopadhyay49% | $78 → $78 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2025 | Buy Now | 46.98% | RBC Capital | Luca Issi40% | $24 → $26 | Maintains | Sector Perform | Get Alert |
| 02/03/2025 | Buy Now | 352.25% | HC Wainwright & Co. | Patrick Trucchio45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2025 | Buy Now | — | Cantor Fitzgerald | Rick Bienkowski27% | — | Upgrade | Neutral → Overweight | Get Alert |
| 12/09/2024 | Buy Now | 352.25% | HC Wainwright & Co. | Patrick Trucchio45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2024 | Buy Now | 352.25% | HC Wainwright & Co. | Patrick Trucchio45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 11/06/2024 | Buy Now | 35.67% | RBC Capital | Luca Issi40% | $27 → $24 | Maintains | Sector Perform | Get Alert |
| 11/06/2024 | Buy Now | 120.47% | Leerink Partners | Rick Bienkowski27% | $27 → $39 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/16/2024 | Buy Now | 35.67% | Scotiabank | Greg Harrison48% | → $24 | Initiates | → Sector Perform | Get Alert |
| 09/19/2024 | Buy Now | 52.63% | RBC Capital | Luca Issi40% | $27 → $27 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 09/17/2024 | Buy Now | — | Jones Trading | Soumit Roy33% | — | Initiates | → Hold | Get Alert |
| 09/11/2024 | Buy Now | 290.06% | Stifel | Benjamin Burnett44% | $66 → $69 | Maintains | Buy | Get Alert |
| 08/22/2024 | Buy Now | 352.25% | HC Wainwright & Co. | Patrick Trucchio45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 171.35% | JP Morgan | Eric Joseph43% | $45 → $48 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | 75.25% | Barclays | Gena Wang49% | $33 → $31 | Maintains | Equal-Weight | Get Alert |
| 08/07/2024 | Buy Now | 52.63% | RBC Capital | Luca Issi40% | $27 → $27 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 07/23/2024 | Buy Now | 352.25% | HC Wainwright & Co. | Patrick Trucchio45% | → $80 | Initiates | → Buy | Get Alert |
| 05/08/2024 | Buy Now | 86.55% | Barclays | Gena Wang49% | $42 → $33 | Maintains | Equal-Weight | Get Alert |
| 04/23/2024 | Buy Now | 222.23% | Wedbush | David Nierengarten57% | $57 → $57 | Reiterates | Outperform → Outperform | Get Alert |
| 03/27/2024 | Buy Now | 222.23% | BMO Capital | Kostas Biliouris32% | → $57 | Maintains | Outperform | Get Alert |
| 02/28/2024 | Buy Now | 137.43% | Barclays | Gena Wang49% | $26 → $42 | Maintains | Equal-Weight | Get Alert |
| 02/28/2024 | Buy Now | 97.86% | RBC Capital | Luca Issi40% | $27 → $35 | Maintains | Sector Perform | Get Alert |
| 01/29/2024 | Buy Now | 126.12% | JP Morgan | Eric Joseph43% | $38 → $40 | Upgrade | Neutral → Overweight | Get Alert |
| 12/15/2023 | Buy Now | 97.86% | B of A Securities | Greg Harrison48% | → $35 | Downgrade | Buy → Neutral | Get Alert |
| 12/08/2023 | Buy Now | 69.59% | Jefferies | Michael Yee55% | $75 → $30 | Downgrade | Buy → Hold | Get Alert |
| 10/17/2023 | Buy Now | 80.9% | Cantor Fitzgerald | Rick Bienkowski27% | $56 → $32 | Maintains | Overweight | Get Alert |
| 09/13/2023 | Buy Now | 216.57% | Cantor Fitzgerald | Rick Bienkowski27% | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | Buy Now | 216.57% | Cantor Fitzgerald | Rick Bienkowski27% | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 97.86% | Barclays | Gena Wang49% | $41 → $35 | Maintains | Equal-Weight | Get Alert |
| 08/09/2023 | Buy Now | 165.69% | Credit Suisse | Richard Law43% | $46 → $47 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | 216.57% | Citigroup | Samantha Semenkow32% | $60 → $56 | Maintains | Buy | Get Alert |
| 05/11/2023 | Buy Now | 137.43% | RBC Capital | Luca Issi40% | $50 → $42 | Maintains | Sector Perform | Get Alert |
| 05/11/2023 | Buy Now | 131.78% | Barclays | Gena Wang49% | $45 → $41 | Maintains | Equal-Weight | Get Alert |
| 05/11/2023 | Buy Now | 239.18% | Citigroup | Samantha Semenkow32% | $62 → $60 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | 109.16% | Bernstein | William Pickering38% | → $37 | Initiates | → Market Perform | Get Alert |
| 03/01/2023 | Buy Now | 493.57% | Wells Fargo | Yanan Zhu39% | $125 → $105 | Maintains | Overweight | Get Alert |
| 02/01/2023 | Buy Now | 250.49% | Cantor Fitzgerald | Rick Bienkowski27% | → $62 | Initiates | → Overweight | Get Alert |
| 01/23/2023 | Buy Now | 335.29% | SVB Leerink | Mani Foroohar47% | $81 → $77 | Maintains | Outperform | Get Alert |
| 12/20/2022 | Buy Now | 273.1% | BMO Capital | Kostas Biliouris32% | $61 → $66 | Upgrade | Market Perform → Outperform | Get Alert |
| 12/13/2022 | Buy Now | 250.49% | Citigroup | Samantha Semenkow32% | → $62 | Initiates | → Buy | Get Alert |
| 11/08/2022 | Buy Now | 199.61% | Credit Suisse | Richard Law43% | $65 → $53 | Maintains | Neutral | Get Alert |
| 11/07/2022 | Buy Now | 357.9% | SVB Leerink | Mani Foroohar47% | $82 → $81 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | 239.18% | Barclays | Gena Wang49% | $38 → $60 | Maintains | Equal-Weight | Get Alert |
| 08/10/2022 | Buy Now | 538.8% | SVB Leerink | Rick Bienkowski27% | $118 → $113 | Maintains | Outperform | Get Alert |
| 06/17/2022 | Buy Now | 131.78% | BMO Capital | Kostas Biliouris32% | → $41 | Initiates | → Market Perform | Get Alert |
FAQ
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ:BEAM) was reported by Guggenheim on May 7, 2025. The analyst firm set a price target for $55.00 expecting BEAM to rise to within 12 months (a possible 210.92% upside). 28 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Beam Therapeutics (BEAM)?
The latest analyst rating for Beam Therapeutics (NASDAQ:BEAM) was provided by Guggenheim, and Beam Therapeutics maintained their buy rating.
When was the last upgrade for Beam Therapeutics (BEAM)?
The last upgrade for Beam Therapeutics Inc happened on March 28, 2025 when B of A Securities raised their price target to $42. B of A Securities previously had a neutral for Beam Therapeutics Inc.
When was the last downgrade for Beam Therapeutics (BEAM)?
The last downgrade for Beam Therapeutics Inc happened on December 15, 2023 when B of A Securities changed their price target from N/A to $35 for Beam Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Beam Therapeutics (BEAM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on May 7, 2025 so you should expect the next rating to be made available sometime around May 7, 2026.
Is the Analyst Rating Beam Therapeutics (BEAM) correct?
While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a maintained with a price target of $78.00 to $55.00. The current price Beam Therapeutics (BEAM) is trading at is $17.69, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
